查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1831918

胃轻瘫药物市场报告（按疾病类型、药物类别、配销通路和地区）2025-2033

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球胃轻瘫药物市场规模达67亿美元。展望未来， IMARC Group预计到2033年，市场规模将达到98亿美元，2025-2033年期间的复合年增长率（CAGR）为4.06%。糖尿病性胃轻瘫盛行率的上升、药物开发技术的进步、医护人员和患者认知度的提高、医疗保健投资的蓬勃发展、临床试验的增多、糖尿病和帕金森氏症等慢性疾病的激增以及监管支持，都是推动市场成长的一些因素。

胃轻瘫药物市场趋势：

胃轻瘫盛行率不断上升

胃轻瘫盛行率的不断上升，尤其是在糖尿病患者中，正在加速市场成长。 2021年，印度约有7,490万20至79岁的糖尿病患者，预计2045年将达到1.249亿人。此外，糖尿病患者数量的增加也催生了对高效治疗和管理的需求，这进一步推动了市场的成长。此外，主要製药公司正在积极开发新的标靶治疗方案，这进一步为市场创造了积极的前景。

药物开发技术的进步

不断增长的在研产品数量以及新产品的开发正在促进市场成长。此外，为提高胃轻瘫治疗的有效性和安全性，药物研发 (R&D) 投资的激增也推动了市场成长。胃轻瘫药物市场近期的机会，例如高通量筛选、计算和个人化医疗的出现，使得能够精准快速地识别潜在候选药物，正在为市场成长提供动力。此外，缓释製剂和新型给药机制等药物传递系统的进步，使得药物的给药和吸收更加高效，从而推动了市场成长。

医疗保健专业人员和患者的意识不断提高

医疗保健专业人员和患者对胃轻瘫的认识不断提高，大大促进了市场成长。随着认知度的提高，患者的诊断更加准确，这进一步推动了市场成长。此外，胃肠病学家等医疗保健专业人员对胃轻瘫症状的认识也越来越敏锐，这有助于更早地识别胃轻瘫，从而更好地照顾患者。此外，患者对胃轻瘫症状和治疗的认识不断提高，以及新型治疗方案的出现，也推动了胃轻瘫药物的需求。

胃轻瘫药物市场细分：

依疾病类型分类：

  • 糖尿病性胃轻瘫
  • 特发性胃轻瘫
  • 术后胃轻瘫
  • 其他的

特发性胃轻瘫占大部分市场份额

特发性胃轻瘫细分市场的发展源于人们对该疾病影响的日益认识以及对有效治疗方案的需求。特发性胃轻瘫无法确定根本病因，由于其难以预测的性质和严重程度，给患者和医疗保健提供者带来了巨大的挑战。临床医师对特发性胃轻瘫的认识和理解不断提高，诊断更加精准，并更加重视开发标靶治疗。诊断技术的进步，例如影像学和运动功能测试的改进，正在增强识别特发性胃轻瘫病例并将其与其他胃肠道疾病区分开来的能力，从而促进胃轻瘫药物市场的成长。此外，针对特发性胃轻瘫的研究经费和临床试验的增加，正在推动药物开发的创新，带来新的治疗方案。

按毒品类别分类：

  • 促动力剂
  • 止吐药
  • 肉毒桿菌注射

促动力剂占据产业最大份额

胃轻瘫药物市场的促动力药物细分市场受多种关键因素驱动，例如胃轻瘫盛行率的不断上升，尤其是在糖尿病患者和老年人群中，这带来了对有效促动力药物的强劲需求。促动力药物可以增强胃动力并促进胃排空，对于控制胃轻瘫症状（包括噁心和呕吐）至关重要。药物研发领域的重大进展带来了促动力药物製剂的改进，这些製剂疗效更佳、副作用更少，从而推动了胃轻瘫药物市场的收入成长。正在进行的促动力药物研究和临床试验有助于更好地了解其作用机制和潜在益处，从而拓展其临床应用。此外，医护人员和患者对胃轻瘫的认识不断提高，这凸显了对有效治疗的需求，这进一步推动了对促动力药物的需求。

按配销通路细分：

  • 医院和诊所
  • 药局
  • 网上商店

医院和诊所是主要的细分市场

胃轻瘫药物市场的医院和诊所细分市场，受日益增长的专科医疗护理和先进胃轻瘫治疗方案需求的驱动。胃轻瘫盛行率不断上升，尤其是在糖尿病患者中，需要更全面、更频繁的医疗干预，也推动了该细分市场的发展。医院和诊所提供一系列诊断和治疗服务，包括专业的胃肠病科室和先进的影像技术，这些对于胃轻瘫的准确诊断和有效管理至关重要。此外，糖尿病和帕金森氏症等慢性疾病的发生率上升，这些疾病通常会导致胃轻瘫，进一步推动了住院治疗的需求。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美引领市场，占据胃轻瘫药物最大市场份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是胃轻瘫药物最大的区域市场。

北美地区市场受胃轻瘫盛行率迅速上升的驱动，尤其是在糖尿病族群中，显着影响了对有效治疗的需求。糖尿病的高发生率是导致胃轻瘫的主要因素，因为糖尿病性胃轻瘫是常见的併发症。此外，胃轻瘫药物市场近期的发展和进步，例如高通量筛选和新型给药系统，提高了胃轻瘫药物的疗效和安全性，有助于市场扩张。此外，该地区还受益于强大的医疗基础设施和在研发方面的大量投资，从而能够更快地推出创新疗法。此外，医护人员和患者对胃轻瘫及其管理的认识不断提高，这也促进了市场的成长，从而促进了早期诊断和更积极的治疗方法。

本报告回答的关键问题

  • 2024 年全球胃轻瘫药物市场规模是多少
  • 2025-2033年全球胃轻瘫药物市场的预期成长率是多少
  • COVID-19 对全球胃轻瘫药物市场有何影响
  • 推动全球胃轻瘫药物市场的关键因素有哪些
  • 根据疾病类型，全球胃轻瘫药物市场如何分布
  • 根据药物类别，全球胃轻瘫药物市场如何分布
  • 根据配销通路，全球胃轻瘫药物市场如何分布
  • 全球胃轻瘫药物市场的主要区域有哪些
  • 全球胃轻瘫药物市场的主要参与者/公司有哪些

本报告回答的关键问题

  • 2024年全球胃轻瘫药物市场规模？ 2025-2033年全球胃轻瘫药物市场的预期成长率为何？
  • COVID-19 对全球胃轻瘫药物市场有何影响？
  • 推动全球胃轻瘫药物市场发展的关键因素有哪些？
  • 根据疾病类型，全球胃轻瘫药物市场是如何分布的？
  • 根据药物类别，全球胃轻瘫药物市场是如何分布的？
  • 根据配销通路，全球胃轻瘫药物市场分布如何？
  • 全球胃轻瘫药物市场的主要地区有哪些？
  • 全球胃轻瘫药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球胃轻瘫药物市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依疾病类型

  • 糖尿病性胃轻瘫
  • 特发性胃轻瘫
  • 术后胃轻瘫
  • 其他的

第七章：市场区隔：依药品类别

  • 促动力剂
  • 止吐药
  • 肉毒桿菌注射

第八章：市场区隔：按配销通路

  • 医院和诊所
  • 药局
  • 网上商店

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Abbvie Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • Evoke Pharma
    • Medtronic plc
    • Neurogastrx Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
Product Code: SR112025A4608

The global gastroparesis drugs market size reached USD 6.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.06% during 2025-2033. The rising prevalence of diabetic gastroparesis, advancements in drug development technologies, increasing awareness among healthcare professionals and patients, burgeoning healthcare investments, growing clinical trials, surging chronic conditions like diabetes and Parkinson's, and regulatory support are some of the factors propelling the market growth

Gastroparesis Drugs Market Trends:

Increasing Prevalence of Gastroparesis

The escalating prevalence of gastroparesis, especially in diabetes patients, is accelerating the market growth. In 2021 India had about 74.9 million people with diabetes aged between 20-79, which is expected to reach 124.9 million by 2045. Moreover, the increasing number of patients with diabetes has burgeoned the need for efficient treatment and management, which is further providing a considerable thrust to the market growth. Additionally, the key pharmaceutical companies are actively working to develop new and targeted therapy options, which is further creating a positive outlook for the market.

Advancements in Drug Development Technologies

The growing number of products in the pipeline and the development of new product variants are augmenting the market growth. Furthermore, the surging investments in pharmaceutical research and development (R&D) to improve the efficacy and safety of gastroparesis therapies are fueling the market growth. The gastroparesis drugs market recent opportunities, such as the advent of high-throughput screening, computational and personalized medicine, enabling precise and quick identification of potential candidates are providing an impetus to the market growth. Apart from this, the advancements in drug delivery systems, such as extended-release formulations and novel drug-delivery mechanisms, are rendering an efficient administration and absorption of medications, thereby impelling the market growth.

Rising Awareness Among Healthcare Professionals and Patients

The growing awareness among both healthcare professionals and patients regarding gastroparesis is significantly facilitating the market growth. Patients with the condition are more accurately diagnosed due to the subsequent increase in awareness, which further provides a considerable thrust to the market growth. Additionally, healthcare professionals, such as gastroenterologists, are becoming more acutely aware of the symptoms, which further helps recognize gastroparesis sooner, leading to better patient care. Moreover, burgeoning patient awareness about the symptoms and treatment of gastroparesis and the availability of novel treatment options are propelling the gastroparesis drugs demand.

Gastroparesis Drugs Market Segmentation:

Breakup by Disease Type:

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-surgical Gastroparesis
  • Others

Idiopathic gastroparesis accounts for the majority of the market share

The idiopathic gastroparesis segment is driven by the growing recognition of the condition's impact and the need for effective treatment solutions. Idiopathic gastroparesis, where no underlying cause can be identified, poses significant challenges for patients and healthcare providers due to its unpredictable nature and severity. Increased awareness and understanding of idiopathic gastroparesis among clinicians are leading to more accurate diagnoses and a focus on developing targeted therapies. Advances in diagnostic technologies, such as improved imaging and motility testing, are enhancing the ability to identify idiopathic gastroparesis cases and differentiate them from other gastrointestinal disorders, thereby boosting the gastroparesis drugs market growth. Furthermore, the rise in research funding and clinical trials dedicated to idiopathic gastroparesis is driving innovation in drug development, leading to new therapeutic options.

Breakup by Drug Class:

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

Prokinetic agents hold the largest share of the industry

The prokinetic agents segment in the gastroparesis drugs market is driven by several key factors, such as the increasing prevalence of gastroparesis, particularly among diabetic and elderly populations, which creates a strong demand for effective prokinetic therapies. Prokinetic agents, which enhance gastric motility and facilitate stomach emptying, are essential in managing the symptoms of gastroparesis, including nausea and vomiting. Significant advancements in drug development leading to improved prokinetic formulations with enhanced efficacy and fewer side effects are boosting gastroparesis drugs market revenue. The ongoing research and clinical trials focused on prokinetic agents contribute to a better understanding of their mechanisms and potential benefits, thereby expanding their clinical applications. Additionally, the growing awareness of gastroparesis among healthcare professionals and patients underscores the need for effective treatments, further driving the demand for prokinetic agents.

Breakup by Distribution Channel:

  • Hospitals and Clinics
  • Pharmacies
  • Online Stores

Hospitals and clinics represent the leading market segment

The hospitals and clinics segment in the gastroparesis drugs market is driven by the increasing demand for specialized medical care and advanced treatment options for managing gastroparesis. The segment benefits from the escalating prevalence of gastroparesis, particularly among diabetic patients, necessitating more comprehensive and frequent medical interventions. Hospitals and clinics offer a range of diagnostic and therapeutic services, including specialized gastroenterology departments and advanced imaging technologies, which are crucial for accurate diagnosis and effective management of gastroparesis. Additionally, the rise in chronic conditions such as diabetes and Parkinson's disease, which often lead to gastroparesis, further drives the need for hospital-based treatments.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest gastroparesis drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for gastroparesis drugs.

The North America regional market is driven by the burgeoning prevalence of gastroparesis, particularly among the diabetic population, which significantly impacts demand for effective treatments. The high incidence of diabetes is a major contributing factor, as diabetic gastroparesis is a common complication. Additionally, the gastroparesis drugs market recent developments and advancements, such as high-throughput screening and novel drug delivery systems, enhancing the efficacy and safety profiles of gastroparesis medications are aiding in market expansion. Besides this, the region also benefits from robust healthcare infrastructure and significant investments in research and development, enabling faster introduction of innovative treatments. Moreover, the increasing awareness among healthcare professionals and patients about gastroparesis and its management is strengthening the market growth, leading to earlier diagnosis and more proactive treatment approaches.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the gastroparesis drugs industry include Abbott Laboratories, Abbvie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Becton Dickinson and Company, Boston Scientific Corporation, Evoke Pharma, Medtronic plc, Neurogastrx Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, etc.
  • The key gastroparesis drugs companies are actively engaged in several strategic initiatives to advance their position and address the growing demand for effective treatments. They are investing heavily in research and development (R&D) to discover and develop new drugs that target the underlying mechanisms of gastroparesis more effectively. These companies are focusing on innovative drug formulations, including extended-release and novel delivery systems, to enhance the efficacy and patient compliance of treatments. Collaborations and partnerships with research institutions and academic organizations are being pursued to leverage external expertise and resources, which accelerates the development of new therapies. Additionally, leading players are expanding their clinical trial programs to test new drug candidates and gather crucial data to support regulatory approvals. They are also actively seeking regulatory support to expedite the approval process for new treatments, aiming to bring innovative solutions to market more quickly.

Key Questions Answered in This Report

  • 1.What was the size of the global gastroparesis drugs market in 2024?
  • 2.What is the expected growth rate of the global gastroparesis drugs market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global gastroparesis drugs market?
  • 4.What are the key factors driving the global gastroparesis drugs market?
  • 5.What is the breakup of the global gastroparesis drugs market based on the disease type?
  • 6.What is the breakup of the global gastroparesis drugs market based on the drug class?
  • 7.What is the breakup of the global gastroparesis drugs market based on the distribution channel?
  • 8.What are the key regions in the global gastroparesis drugs market?
  • 9.Who are the key players/companies in the global gastroparesis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastroparesis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Diabetic Gastroparesis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Idiopathic Gastroparesis
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Post-surgical Gastroparesis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Prokinetic Agents
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antiemetic Agents
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Botulinum Toxin Injections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbvie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bausch Health Companies Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Becton Dickinson and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Boston Scientific Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Evoke Pharma
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Neurogastrx Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sanofi S.A.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Theravance Biopharma
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Gastroparesis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastroparesis Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Gastroparesis Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Gastroparesis Drugs Market: Breakup by Disease Type (in %), 2024
  • Figure 5: Global: Gastroparesis Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 6: Global: Gastroparesis Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Gastroparesis Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Gastroparesis Drugs (Diabetic Gastroparesis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Gastroparesis Drugs (Idiopathic Gastroparesis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Gastroparesis Drugs (Post-surgical Gastroparesis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Gastroparesis Drugs (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Gastroparesis Drugs (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Gastroparesis Drugs (Prokinetic Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Gastroparesis Drugs (Prokinetic Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Gastroparesis Drugs (Antiemetic Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Gastroparesis Drugs (Antiemetic Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Gastroparesis Drugs (Botulinum Toxin Injections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Gastroparesis Drugs (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Gastroparesis Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Gastroparesis Drugs (Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Gastroparesis Drugs (Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Gastroparesis Drugs (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Gastroparesis Drugs (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Gastroparesis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Gastroparesis Drugs Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Gastroparesis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Gastroparesis Drugs Industry: SWOT Analysis
  • Figure 78: Global: Gastroparesis Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Gastroparesis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastroparesis Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Gastroparesis Drugs Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 3: Global: Gastroparesis Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 4: Global: Gastroparesis Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Gastroparesis Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Gastroparesis Drugs Market: Competitive Structure
  • Table 7: Global: Gastroparesis Drugs Market: Key Players